Evaluation of Home Blood Pressure in Patients Undergoing Anticancer Drug Therapy - Feasibility Study: A Multicenter Observational Study

Evaluation of Home Blood Pressure in Patients Undergoing Anticancer Drug Therapy - Evaluation of Home Blood Pressure in Patients Undergoing Anticancer Drug Therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057740

Enrollment

Registered

2025-04-29

Start date

2025-03-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Malignant Tumors

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients diagnosed with a malignant tumor - Patients who are initiating or currently undergoing treatment with an oral anti-angiogenic agent (anti-cancer drug), including those receiving combination therapy with non-pharmacological treatments such as surgery or radiation therapy, as well as those with a history of hypertension - Patients capable of measuring home blood pressure (i.e., those who own an upper-arm cuff blood pressure monitor)

Exclusion criteria

Exclusion criteria: - Individuals with an ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) of 3 or higher - Individuals deemed unsuitable for inclusion by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Blood pressure values (Comparison of clinic blood pressure and home blood pressure in patients undergoing anticancer drug therapy)	—

Secondary

Measure	Time frame
Blood biochemical tests, urinalysis (common general clinical parameters), adverse event evaluation, and questionnaire surveys will be conducted to: - Assess the relationship between the difference in clinic blood pressure and home blood pressure during anticancer drug therapy, as well as the longitudinal changes in home blood pressure and urinary protein excretion (g/gCre) and estimated daily salt intake. - Evaluate the relationship between longitudinal changes in home blood pressure and medication status during anticancer drug therapy. - Assess the dropout rate and adherence rate of home blood pressure measurements. - Evaluate the relationship between longitudinal changes in various parameters and medication status during anticancer drug therapy. Additionally, as exploratory outcomes, we will examine whether longitudinal changes in home blood pressure during anticancer drug therapy are associated with adverse events and changes in questionnaire survey results over time.	—

Measure

Time frame

Blood biochemical tests, urinalysis (common general clinical parameters), adverse event evaluation, and questionnaire surveys will be conducted to: - Assess the relationship between the difference in clinic blood pressure and home blood pressure during anticancer drug therapy, as well as the longitudinal changes in home blood pressure and urinary protein excretion (g/gCre) and estimated daily salt intake. - Evaluate the relationship between longitudinal changes in home blood pressure and medication status during anticancer drug therapy. - Assess the dropout rate and adherence rate of home blood pressure measurements. - Evaluate the relationship between longitudinal changes in various parameters and medication status during anticancer drug therapy. Additionally, as exploratory outcomes, we will examine whether longitudinal changes in home blood pressure during anticancer drug therapy are associated with adverse events and changes in questionnaire survey results over time.

—

Countries

Japan

Contacts

Public ContactSatoshi Morimoto

Tokyo Women's Medical University Adachi Medical Center Division of Medicine

morimoto.satoshi@twmu.ac.jp03-3757-0111

Outcome results